

AbbVie Inc.
Form 4
April 30, 2015

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
GONZALEZ RICHARD A

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO, IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ABBV]

3. Date of Earliest Transaction
(Month/Day/Year)
04/28/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
Chairman of the Board and CEO

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, \$0.01 par value	04/28/2015		M		175,477	A	\$ 35.88
Common stock, \$0.01 par value	04/28/2015		S		1,800	D	\$ 64.5
Common stock, \$0.01 par value	04/28/2015		S		800	D	\$ 64.52

Edgar Filing: AbbVie Inc. - Form 4

Common stock, \$0.01 par value	04/28/2015	S	400	D	\$ 64.53	654,624	D
Common stock, \$0.01 par value	04/28/2015	S	2,100	D	\$ 64.56	652,524	D
Common stock, \$0.01 par value	04/28/2015	S	1,300	D	\$ 64.57	651,224	D
Common stock, \$0.01 par value	04/28/2015	S	300	D	\$ 64.58	650,924	D
Common stock, \$0.01 par value	04/28/2015	S	800	D	\$ 64.59	650,124	D
Common stock, \$0.01 par value	04/28/2015	S	5,600	D	\$ 64.6	644,524	D
Common stock, \$0.01 par value	04/28/2015	S	3,548	D	\$ 64.61	640,976	D
Common stock, \$0.01 par value	04/28/2015	S	900	D	\$ 64.62	640,076	D
Common stock, \$0.01 par value	04/28/2015	S	3,000	D	\$ 64.64	637,076	D
Common stock, \$0.01 par value	04/28/2015	S	8,100	D	\$ 64.65	628,976	D
Common stock, \$0.01 par value	04/28/2015	S	200	D	\$ 64.655	628,776	D
	04/28/2015	S	3,800	D	\$ 64.66	624,976	D

Edgar Filing: AbbVie Inc. - Form 4

Common stock, \$0.01 par value							
Common stock, \$0.01 par value	04/28/2015	S	2,500	D	\$ 64.67	622,476	D
Common stock, \$0.01 par value	04/28/2015	S	4,317	D	\$ 64.68	618,159	D
Common stock, \$0.01 par value	04/28/2015	S	1,805	D	\$ 64.685	616,354	D
Common stock, \$0.01 par value	04/28/2015	S	3,200	D	\$ 64.69	613,154	D
Common stock, \$0.01 par value	04/28/2015	S	400	D	\$ 64.695	612,754	D
Common stock, \$0.01 par value	04/28/2015	S	34,900	D	\$ 64.7	577,854	D
Common stock, \$0.01 par value	04/28/2015	S	1,100	D	\$ 64.705	576,754	D
Common stock, \$0.01 par value	04/28/2015	S	8,100	D	\$ 64.71	568,654	D
Common stock, \$0.01 par value	04/28/2015	S	300	D	\$ 64.715	568,354	D
Common stock, \$0.01 par value	04/08/2015	S	6,994	D	\$ 64.72	561,360	D
	04/28/2015	S	1,400	D	\$ 64.725	559,960	D

Common stock, \$0.01 par value

Common stock, \$0.01 par value 04/28/2015 S 4,000 D \$ 64.73 555,960 D

Common stock, \$0.01 par value 04/28/2015 S 900 D \$ 64.735 555,060 D

Common stock, \$0.01 par value 04/28/2015 S 400 D \$ 64.7375 554,660 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount of Number of Shares
Option (right to buy) ⁽¹⁾	\$ 35.88	04/28/2015		M	175,477	02/14/2014 02/13/2023	Common stock 175,477

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GONZALEZ RICHARD A 1 N. WAUKEGAN ROAD NORTH CHICAGO, IL 60064	X		Chairman of the Board and CEO	

Signatures

Steven L. Scrogam, attorney-in-fact for Richard A.
Gonzalez

04/30/2015

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

Form 1 of 3. These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.